Compare REBN & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REBN | KALA |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 13.3M |
| IPO Year | 2017 | 2017 |
| Metric | REBN | KALA |
|---|---|---|
| Price | $1.26 | $0.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 51.2K | ★ 56.8K |
| Earning Date | 04-22-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,094,628.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 36.54 | N/A |
| 52 Week Low | $0.91 | $0.07 |
| 52 Week High | $2.95 | $20.58 |
| Indicator | REBN | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 29.61 |
| Support Level | $1.20 | $0.56 |
| Resistance Level | $2.02 | $0.72 |
| Average True Range (ATR) | 0.12 | 0.12 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 31.71 | 4.41 |
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is a company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in two reportable segments: Reborn Coffee, which includes both the wholesale and retail sales of coffee, water, and other beverages, and Reborn Logistics, which provides freight forwarding services.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.